Image Core Lab (ICL), is a clinical research provider for imaging in clinical trials. We provide Charter Development, Image Masking, blinding and prepare blinded images for independent review under ICH-GCP concerns and Independent central reviews by Board certified radiologists, ICL will deal with all aspects of Imaging in Clinical Trials.     
 We propose to leverage our expertise in imaging and related image management technologies and our experience in clinical trial radiology to deliver high end services and technology to CRO’s and Sponsor companies. The essence of ICL is to use our efficiencies, expertise and technology in imaging to reduce costs and drug development cycle times in the clinical trial space.
  

• Our primary target market is comprised of pharmaceutical, biotechnology, and medical device companies with products in different phases of clinical development (Phase I, Phase II, Phase III, or Phase IV)
• Our therapeutic areas of expertise include: oncology, musculoskeletal conditions, and cardiology, central nervous system, neurovascular, and metabolic diseases
• ICL offers services and technology solutions with clear benefits for pharmaceutical and medical device development which include:
• - Cost benefit for clinical trials – because of higher precision in measurement, trials can be powered with fewer patients,
•    thereby lowering clinical costs
• - The company’s ability to produce almost “real-time” clinical trial image analysis eliminates a common clinical trial
•    bottleneck
• Companies looking to expand and enter into the emerging markets in India and Asia (APAC area) will be benefited by our existing networks and strong position in these geographies